Gold bars to be exempt from tariffs, White House clarifies
DUBLIN - Investment management firm BlackRock (NYSE:BLK), Inc. has increased its stake in biopharmaceutical company Alkermes (NASDAQ:ALKS) plc, according to a disclosure filed with the Irish Takeover Panel on Friday.
The filing shows that BlackRock acquired an additional 14,815 ordinary shares with voting rights in Alkermes on Thursday, August 7, 2025. Following this transaction, BlackRock now holds a total of 28,066,227 shares, representing 17% of Alkermes’ total voting securities.
The disclosure was made under Rule 6 of the Irish Takeover Panel Act’s Substantial Acquisition Rules, which requires notification when significant stakes in publicly traded companies are acquired.
Alkermes, headquartered in Dublin, Ireland, is a global biopharmaceutical company focused on developing innovative medicines for central nervous system diseases and cancer.
The transaction details were disclosed through a Form SAR 6 filing submitted to the Stock Exchange and the Irish Takeover Panel, as required by regulatory guidelines. The form was signed by Jana Blumenstein on behalf of BlackRock.
The disclosure did not provide information about BlackRock’s investment strategy or reasons behind the increased stake in Alkermes.
This information was reported based on a regulatory press release statement filed with the London Stock Exchange (LON:LSEG)’s news service, RNS.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.